Based on this discovery, we tested the effect of paclitaxel, a first-line chemotherapy drug for ovarian cancer, on the knockdown and overexpression of CRTC2 in ovarian cancer cell lines. This evidence concerns the gene CRTC2 and ovarian carcinoma.